Anavex Life Sciences Corp. (NASDAQ: AVXL) Attends 31st Annual ROTH Conference
Anavex Life Sciences (NASDAQ: AVXL) is a biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, recently completed a successful phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. For more information, visit the company's website at…







